Schizoaffective Disorder, Schizophrenia
Conditions
Brief summary
The goals of this study are to: Determine the blood levels of intramuscular (IM) olanzapine depot in patients at different points in time after an injection, and compare these levels to the amount of olanzapine in the blood of patients after treated by oral administration with Zyprexa (olanzapine) tablets or by intramuscular administration with Zyprexa IntraMuscular (olanzapine for injection).
Interventions
Sponsors
Eli Lilly and Company
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 76 Years
Healthy volunteers
No
Inclusion criteria
* Patients must have schizophrenia or schizoaffective disorders. * Each patient must have a level of understanding sufficient to complete all tests and examinations required by the protocol, and to provide informed consent. * Patient must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry. * Female patients must not be pregnant or breast-feeding. * Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia or schizoaffective disorder.
Countries
Australia, Belgium, Brazil, Croatia, Czechia, Mexico, Slovakia, Spain
Outcome results
None listed